RXST vs AMPH Stock Comparison: AI Score, Valuation, Performance and Upside
RXST (RxSight) and AMPH (Amphastar Pharmaceuticals) are both niche healthcare companies with differentiated product strategies — RxSight has a unique adjustable IOL system enabling post-cataract-surgery vision fine-tuning that no competitor replicates, requiring LDD device network expansion for commercial scale, while Amphastar provides a diversified portfolio of difficult-to-manufacture specialty injectable and inhalation pharmaceuticals with vertically integrated manufacturing. RxSight is a high-growth premium medical device; Amphastar is a profitable specialty generic pharma.
RXST vs AMPH is unique adjustable IOL ophthalmic device with post-surgery vision customization capability (RxSight's Light Adjustable Lens providing ophthalmologists a differentiated premium IOL system with no direct competition, growing through LDD device network expansion and premium IOL adoption) versus diversified specialty injectable pharmaceutical manufacturer with vertically integrated production (Amphastar's portfolio of enoxaparin, glucagon, epinephrine, and naloxone providing stable hospital injectable revenue while developing biosimilars) — premium medical device growth versus specialty generic pharma stability.
AMPH holds the edge across 4 of 5 key metrics in this comparison. AMPH leads on both 1-year return (-0.87%) and forward P/E quality (7.47x vs -6.69x for RXST), a relatively favorable combination of momentum and valuation. AMPH leads on both revenue growth (5.40%) and operating margin (21.60%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for RXST (+62.42%) than for AMPH (-5.38%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Believe the Light Adjustable Lens's unique post-surgery vision optimization capability will drive sustained ophthalmologist adoption and premium pricing as cataract surgery patients increasingly seek optimal visual outcomes
- Value RxSight's proprietary, clinically differentiated technology with no direct competition as creating pricing power and defensible market position in the premium IOL segment
- Are comfortable with a medical device company that monetizes through a capital-equipment-plus-consumables model (LDD devices placed at practices + LAL lens sales per procedure)
- Want specialty pharmaceutical exposure with diversified injectable and inhalation product revenue providing more stability than single-product biotech companies
- Value Amphastar's vertically integrated manufacturing providing cost advantages and supply reliability in the injectable pharmaceutical market
- See Amphastar's biosimilar programs (insulin glargine) as providing upside potential beyond the core generic injectable business if biosimilar programs achieve approval and market penetration
| Metric | RXST | AMPH |
|---|---|---|
| AI scorei | 23.6 | 31.7 |
| AI ranki | #3481 | #2096 |
| Latest closei | $4.66 | $26.13 |
| 1M returni | -26.96% | +18.66% |
| 6M returni | -25.56% | +37.45% |
| 1Y returni | -48.54% | -0.87% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RXST | AMPH |
|---|---|---|
| 1Y ago | $5.15K (-48.5%) started 2025-09-25 | $9.91K (-0.9%) started 2025-09-25 |
| 5Y ago | $3.44K (-65.6%) started 2021-09-27 | $13.57K (+35.7%) started 2021-09-27 |
| 10Y ago | $2.91K (-70.9%) started 2021-07-30 | $13.35K (+33.5%) started 2016-09-26 |
Hypothetical — past performance does not guarantee future results.
| Metric | RXST | AMPH |
|---|---|---|
| Market capi | $193.82M | $1.01B |
| Trailing P/Ei | N/A | 14.07 |
| Forward P/Ei | -6.69 | 7.47 |
| Price/Salesi | 1.52 | N/A |
| EV/Revenuei | -0.03 | 1.93 |
| Analyst targeti | $7.57 | $22.50 |
| Target upsidei | +62.42% | -5.38% |
| Metric | RXST | AMPH |
|---|---|---|
| Revenue growthi | 0.30% | 5.40% |
| Earnings growthi | N/A | 4.70% |
| EPS growthi | N/A | +4.70% |
| FCF margini | -5.28% | +31.52% |
| Operating margini | -40.81% | 21.60% |
| Profit margini | -36.80% | 10.76% |
| ROIC proxyi | -17.34% | 10.30% |
| Return on equityi | -17.34% | 10.30% |
| Dividend yieldi | 0.00% | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 1.16 | 0.92 |
| Debt/equityi | 4.02 | 89.61 |
| Current ratioi | 4.07 | 2.40 |
| Quick ratioi | 3.57 | 1.66 |
Over the past year, RXST and AMPH have moved weakly in the same direction (correlation of 0.25), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RXST | AMPH |
|---|---|---|---|
| 1Y | Growthi | -48.54% | -0.87% |
| CAGRi | -48.56% | -0.87% | |
| Volatilityi | 63.29% | 51.32% | |
| Sharpe ratioi | -0.81 | 0.17 | |
| Sortino ratioi | -1.14 | 0.21 | |
| Max drawdowni | 64.94% | 42.62% | |
| Current drawdowni | 64.40% | 11.12% | |
| Avg drawdowni | 37.19% | 19.84% | |
| Ulcer Indexi | 42.73% | 23.84% | |
| Max daily dropi | 14.45% | 23.63% | |
| Max wkly dropi | 23.97% | 29.09% | |
| 5Y | Growthi | -65.63% | +35.67% |
| CAGRi | -19.26% | +6.30% | |
| Volatilityi | 66.90% | 45.78% | |
| Sharpe ratioi | -0.04 | 0.27 | |
| Sortino ratioi | -0.06 | 0.37 | |
| Max drawdowni | 92.86% | 74.05% | |
| Current drawdowni | 92.75% | 59.80% | |
| Avg drawdowni | 37.64% | 33.97% | |
| Ulcer Indexi | 50.60% | 41.10% | |
| Max daily dropi | 37.94% | 23.63% | |
| Max wkly dropi | 41.75% | 29.09% | |
| 10Y | Growthi | -70.88% | +33.45% |
| CAGRi | -21.28% | +2.93% | |
| Volatilityi | 68.71% | 42.51% | |
| Sharpe ratioi | -0.06 | 0.18 | |
| Sortino ratioi | -0.08 | 0.24 | |
| Max drawdowni | 92.86% | 74.05% | |
| Current drawdowni | 92.75% | 59.80% | |
| Avg drawdowni | 39.91% | 27.37% | |
| Ulcer Indexi | 51.08% | 33.00% | |
| Max daily dropi | 37.94% | 24.70% | |
| Max wkly dropi | 41.75% | 29.09% |
| Category | RXST | AMPH |
|---|---|---|
| Company | RxSight, Inc. | Amphastar Pharmaceuticals, Inc. |
| Sector | Healthcare - Ophthalmic Medical Devices | Healthcare |
| Industry | Medical Devices | Drug Manufacturers - Specialty & Generic |
| Core business | RxSight is a commercial-stage ophthalmic medical device company commercializing the Light Adjustable Lens (LAL) system for cataract surgery. The LAL is a unique intraocular lens (IOL) that can be non-invasively adjusted after surgical implantation — the surgeon implants the LAL during routine cataract surgery, and then in the weeks following surgery, the lens's prescription (power and astigmatic correction) is fine-tuned using UV light treatment delivered by RxSight's Light Delivery Device (LDD). This allows the ophthalmologist to optimize the patient's vision based on actual post-surgery healing, achieving more precise vision correction than fixed-prescription IOLs that must be calculated before surgery. | Amphastar Pharmaceuticals is a specialty pharmaceutical company focused on difficult-to-manufacture injectable and inhalation products, including generic and branded specialty pharmaceuticals. Amphastar's product portfolio includes: enoxaparin (low molecular weight heparin — blood thinner), glucagon (hypoglycemia emergency treatment), epinephrine products (anaphylaxis treatment — EpiPen generics), naloxone (opioid overdose reversal), inhalation products (albuterol, budesonide, ipratropium), and pharmacy-compounding APIs. Amphastar also has biosimilar development programs (insulin glargine, exenatide biosimilar). Amphastar owns manufacturing facilities in California and China, providing vertically integrated production of injectable drug products. |
| Investor focus | Investors track RxSight's LAL system installations (number of LDD devices placed at ophthalmology practices), LAL unit volume growth (lenses implanted per LDD unit per year — utilization rate), revenue and gross margin trajectory, and the expansion of the LAL practice into new surgeon adopters. | Investors track Amphastar's product revenue mix and gross margin evolution (shift from lower-margin generic injectables toward higher-margin products), new product launch revenue contribution, biosimilar program progress, and operating leverage as higher-margin products scale. |
- First and only adjustable IOL system offering post-surgery vision optimization — the LAL's post-implantation adjustability is a genuinely unique technology in ophthalmic surgery; no competitor offers a comparable post-surgery vision customization capability
- Premium IOL category is growing as more patients opt for enhanced vision correction in cataract surgery — the premium IOL market (multifocal, toric, extended-depth-of-focus lenses) has grown as patients increasingly pay out-of-pocket for better vision outcomes beyond the standard monofocal lens covered by insurance
- Clinical data shows superior vision outcomes versus traditional IOLs — clinical trials demonstrated LAL patients achieving better uncorrected distance vision versus monofocal IOLs; high patient satisfaction and the precision of adjustable correction is clinically compelling
- Vertically integrated manufacturing provides cost advantages in injectable pharmaceuticals — Amphastar manufactures APIs (active pharmaceutical ingredients) and formulates finished products internally, reducing dependency on external API suppliers and providing cost control in a market where supply chain reliability is critical
- Difficult-to-manufacture product portfolio with regulatory complexity barriers — injectable and inhalation drug manufacturing requires substantial FDA regulatory compliance investment; the technical difficulty of injectable drug manufacturing creates higher barriers to entry than oral solid dosage forms
- Enoxaparin market position and diversified injectable portfolio — Amphastar is the leading generic enoxaparin supplier in the U.S.; low-molecular-weight heparins are essential medications in hospital settings; Amphastar's hospital-direct distribution model provides a stable institutional sales channel for its broader injectable portfolio
- Capital-intensive LDD placement limits rapid growth — installing LDD devices at practices requires capital investment and training; surgeons must be credentialed for LAL procedures; the LDD placement network grows incrementally rather than explosively
- Premium IOL pricing requires patient out-of-pocket payment — LAL is a premium upgrade above standard insurance-covered cataract surgery; patient willingness to pay $2,000-4,000+ above insurance coverage for premium IOLs is the key demand driver; economic sensitivity affects premium IOL demand
- Competitive premium IOL alternatives from Alcon, J&J Vision — while LAL is unique, premium IOL alternatives (multifocal Panoptix, extended-depth TECNIS Symfony, toric lenses) compete for the premium IOL upgrade budget; ophthalmologists may continue using familiar premium alternatives
- Generic injectable pricing pressure is structural — generic injectable markets are competitive; pricing erosion as competitors enter markets for established generics (like enoxaparin) reduces revenue over time for any given product; Amphastar must continuously launch new products to offset commodity pricing on older generics
- Biosimilar development is expensive and uncertain — Amphastar's biosimilar programs (insulin glargine) require significant investment and face approval uncertainty; biosimilar markets once launched can be competitive with multiple approved biosimilars
- China manufacturing concentration creates geopolitical supply chain risk — Amphastar's Chinese manufacturing operations provide cost efficiency but create supply chain risk from U.S.-China trade tensions, quality incidents, or regulatory actions at the China facility
Compare more than two at a time
This page is a fixed writeup on RXST and AMPH. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside RXST and AMPH, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.